Glooko and Diasend Merge to Deliver the World’s Premier Diabetes Management Platform
For people either living with or caring for people with diabetes, Glooko and Diasend are well-known for making diabetes management easier by offering best-in-class diabetes management and analytics platforms that facilitate data driven care for patients and clinicians. In a move that will accelerate the overarching mission to make diabetes management easier worldwide, Glooko and Diasend today announced they have merged into a unified company.
“This is a big day for us – we are thrilled to come together to be able to deliver products and services that will offer even more value to patients and healthcare providers around the world,” says Rick Altinger, CEO of Glooko, Inc.
“This is without a doubt the best possible scenario for our two companies, as well as for patients and the care teams that serve them. From our standpoint, this means adding even more functionality to an already very strong technical platform,” says Anders Sonesson, CEO of Diasend AB.
As a combined entity, the new company now serves 4,000 diabetes clinics in 23 countries across 15 languages, impacting tens of millions of people with diabetes. The joint platform downloads data from more than 160 different devices – including glucose meters, insulin pumps, continuous glucose monitors (CGMs) and activity trackers, in total covering over 95% of diabetes devices used worldwide. Together the joint solution enables support for people with diabetes during and in-between doctor visits, as well as in-office diabetes data uploads and analytics. The products also provide smartphone enabled self-management and a population health platform that supports diabetes coaches around the world.
The two companies, which have chosen to unite under the Glooko name, have recently raised $8M in equity financing, led by global venture capital firm Canaan Partners, to accelerate integration and sales efforts. Other investors include Social Capital, Samsung Ventures and Yogen Dalal, Glooko’s founder and partner emeritus at venture capital firm Mayfield fund.
Glooko, based in Mountain View, CA and Diasend, in Gothenburg, Sweden, have both spent recent years perfecting their respective take on the optimal solution for diabetes data management. Recent product announcements show this. Glooko’s recently announced Glooko Advise product line is focused on leveraging diabetes data to deliver personalized medicine recommendations to patients and care teams. Diasend’s recent announcement focused on enabling Abbott’s Freestyle LibreLink patients to see their glucose data alongside pump data. As a combined entity, these and other product delivery initiatives will not only continue, but will also be optimized and accelerated through the larger combined team.
Diasend simplifies life for people with diabetes and facilitates the work of their health care providers by optimizing diabetes data management. The company’s comprehensive and market leading solution involves transmitting, storing and analyzing data from more than 140 different glucose meters, insulin pumps, CGM systems and leading activity trackers – allowing patients and caregivers to easily access the exact same information. Diasend’s products and services, all FDA approved and CE marked, are currently used in 23 countries. Headquarters are located in Gothenburg, Sweden – with subsidiaries in Chicago and London. For more information, please visit www.diasend.com
Glooko is the leading remote patient monitoring platform for diabetes and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant Web and Mobile application designed to improve health outcomes for people with diabetes, which in turn reduces costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 diabetes devices and major fitness and activity trackers and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s population management web app and APIs offer diabetes-centric analytics and insightful reports, graphs and risk flags to health systems and payers. Learn more at http://www.glooko.com and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko .
Michelle de Haaff
Vice President of Marketing and Customer Success
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
PIERRE-FABRE23.6.2018 13:02 | pressemeddelelse
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress
SERVIER23.6.2018 10:12 | pressemeddelelse
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho
SOFTOMOTIVE22.6.2018 17:15 | pressemeddelelse
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA
TX-ASCEND-PERFORMANCE22.6.2018 16:02 | pressemeddelelse
Ascend Performance Materials Announces Price Increase for Intermediate Materials
DELTICOM-AG/MOTO-TYRES.C22.6.2018 15:43 | pressemeddelelse
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk
BOEHRINGER-INGELHEIM22.6.2018 14:02 | pressemeddelelse
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum